Bank of New York Mellon Corp Sells 34,512 Shares of Cencora, Inc. $COR

Bank of New York Mellon Corp cut its holdings in Cencora, Inc. (NYSE:COR) by 3.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,052,912 shares of the company’s stock after selling 34,512 shares during the period. Bank of New York Mellon Corp’s holdings in Cencora were worth $355,621,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Oakworth Capital Inc. bought a new position in shares of Cencora in the 4th quarter worth about $26,000. Elyxium Wealth LLC bought a new position in shares of Cencora in the 4th quarter worth about $27,000. Archer Investment Corp raised its position in shares of Cencora by 134.3% in the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after acquiring an additional 47 shares in the last quarter. Optima Capital LLC bought a new position in shares of Cencora in the 4th quarter worth about $31,000. Finally, Basepoint Wealth LLC acquired a new stake in shares of Cencora in the 4th quarter valued at about $32,000. 97.52% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

COR has been the subject of several research reports. Robert W. Baird reduced their target price on Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. JPMorgan Chase & Co. raised their target price on Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a research note on Tuesday, February 10th. Citigroup reduced their target price on Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. William Blair initiated coverage on Cencora in a research note on Tuesday, April 28th. They issued a “market perform” rating for the company. Finally, Barclays raised their target price on Cencora from $400.00 to $425.00 and gave the company an “overweight” rating in a research note on Friday, February 13th. Twelve investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, Cencora currently has an average rating of “Moderate Buy” and an average target price of $380.25.

Cencora Trading Up 2.5%

NYSE:COR opened at $270.12 on Friday. The firm’s 50 day moving average is $293.70 and its 200 day moving average is $330.94. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40. Cencora, Inc. has a 12 month low of $244.82 and a 12 month high of $377.54. The stock has a market capitalization of $52.55 billion, a PE ratio of 20.71, a price-to-earnings-growth ratio of 1.42 and a beta of 0.59.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business had revenue of $78.36 billion for the quarter, compared to the consensus estimate of $81.09 billion. During the same period in the previous year, the firm earned $4.42 EPS. The company’s revenue was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Sell-side analysts expect that Cencora, Inc. will post 17.79 earnings per share for the current year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date was Friday, May 15th. Cencora’s payout ratio is 18.40%.

Cencora declared that its board has approved a share repurchase plan on Thursday, May 21st that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the company to repurchase up to 3.9% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s board of directors believes its shares are undervalued.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.